Physician profile
Taylor Stabb
NPI 1982062238
$1,994.67
in general payments reported to CMS, 2019-2025
33 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $600 · 2022: $522 · 2023: $465 · 2024: $192 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $396.89 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $342.93 | 2021-2025 | Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $120.01 | 2022 | |
| Amarin Pharma, INC. | $113.34 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.08 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $80.43 | 2021-2024 | |
| Abbvie INC. | $73.09 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $65.32 | 2023-2024 | Rexulti, Nuedexta |
| Boston Scientific Corporation | $56.79 | 2023 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $48.83 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.48 | 2021-2023 | Farxiga, Breztri |
| Dexcom, INC. | $46.34 | 2023-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $44.07 | 2021-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.93 | 2021 | |
| Abbott Laboratories | $36.07 | 2021-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $34.99 | 2021 | |
| Amgen INC. | $34.13 | 2021-2023 | Otezla, Repatha |
| Corcept Therapeutics | $28.89 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $28.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.39 | 2021-2022 | |
| Lilly USA, LLC | $26.65 | 2022-2023 | Jardiance, Emgality |
| Astellas Pharma US INC | $22.61 | 2021 | |
| Sumitomo Pharma America, INC. | $20.61 | 2023 | Gemtesa |
| Inogen, INC. | $20.53 | 2022 | |
| Urovant Sciences INC | $19.07 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.67 | 2023 | Inpefa |
| Sun Pharmaceutical Industries INC. | $17.63 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.53 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $17.51 | 2022 | |
| Pfizer INC. | $16.21 | 2024 | |
| Avanir Pharmaceuticals, INC. | $14.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.48 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Stabb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.